Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.
|ISBN||1445-5994 (Electronic) 1444-0903 (Linking)|
|Authors||Isaacs, M.; Tonks, K. T.; Greenfield, J. R.|
|Responsible Garvan Author|
|Publisher Name||INTERNAL MEDICINE JOURNAL|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/28580740|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/14104|